BrainsWay Ltd. (BWAY), a commercial stage medical device company developing non-invasive neurostimulation products for brain disorders, is not just focused on growing its revenue but also committed to achieving profitability.
The company's flagship technology is Deep Transcranial Magnetic Stimulation, which has received FDA clearance for three indications namely major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com